EyePoint Pharmaceuticals, Inc. — Director's Dealing 2021

Feb 11, 2021

SEC Form 5 — Annual Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-12-31

Reporting Person: Lurker Nancy (Director, See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-15	Stock Option (Right to Buy)	$36.30	G	63750	Disposed	2026-09-15	Common Stock (63750)	Direct
2020-06-15	Stock Option (Right to Buy)	$36.30	G	63750	Acquired	2026-09-15	Common Stock (63750)	Indirect
2020-06-15	Stock Option (Right to Buy)	$17.70	G	16000	Disposed	2027-06-27	Common Stock (16000)	Direct
2020-06-15	Stock Option (Right to Buy)	$17.70	G	16000	Acquired	2027-06-27	Common Stock (16000)	Indirect
2020-06-15	Stock Option (Right to Buy)	$20.40	G	18000	Disposed	2028-06-14	Common Stock (18000)	Direct
2020-06-15	Stock Option (Right to Buy)	$20.40	G	18000	Acquired	2028-06-14	Common Stock (18000)	Indirect
2020-06-15	Stock Option (Right to Buy)	$26.50	G	27132	Disposed	2029-02-21	Common Stock (27132)	Direct
2020-06-15	Stock Option (Right to Buy)	$26.50	G	27132	Acquired	2029-02-21	Common Stock (27132)	Indirect

Footnotes

F1: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediately family members are the sole beneficiaries (the "Family Trust"). The option was originally granted to the reporting person on December 12, 2016 and was exercisable for 85,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 63,750 shares of Common Stock of the Company.

F2: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on December 15, 2017 and was exercisable for 24,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 16,000 shares of Common Stock of the Company.

F3: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 14, 2018 and was exercisable for 54,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 18,000 shares of Common Stock of the Company.

F4: On June 15, 2020, the reporting person transferred the vested portion of an option to purchase Common Stock of the Company to the Family Trust. The option was originally granted to the reporting person on June 25, 2019 and was exercisable for 93,000 shares of Common Stock of the Company. At the time of the transfer, the vested portion of the option consisted of 27,132 shares of Common Stock of the Company.

F5: The option vested and became exercisable in four equal annual installments beginning on September 15, 2017. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of September 15, 2019. The remaining portion of the option retained by the reporting person vested in full as of September 15, 2020.

F6: The option vested and became exercisable in three equal annual installments beginning on June 27, 2018. At the time of the transfer, the portion of the option that was transferred to the Family Trust had vested in full as of June 27, 2019. The remaining portion of the option retained by the reporting person vested in full as of June 27, 2020.

F7: The option vests and becomes exercisable in three equal annual installments beginning on June 14, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of June 14, 2019. The remaining portion of the option retained by the reporting person continues to vest on an annual basis until June 14, 2021.

F8: The option vests and becomes exercisable ratably in 48 monthly installments beginning on March 21, 2019. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full as of May 21, 2020. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until March 21, 2023.

F9: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.